PharmacoEconomics

Cost-effectiveness of Semaglutide and Resmetirom (80 mg and 100 mg) Compared to Standard Treatment for Metabolic Liver Disease in the US

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

A cohort Markov state-transition model was used to evaluate the cost-effectiveness of semaglutide 2.4 mg and resmetirom (80 mg and 100 mg) compared to standard care.

  • Non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis presents significant clinical and economic challenges.
  • Semaglutide 2.4 mg has shown clinical benefits for patients with this condition.
  • Understanding the financial implications of new treatments is crucial for payers.
  • The cost-effectiveness analysis compares new treatment options against standard of care.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Declarations. Conflicts of interest: AM and RL are both employees and shareholders of Novo Nordisk Inc., Plainsboro, NJ, USA. FC is an employee of Genesis Research Group (Hoboken, NJ), which was contracted by Novo Nordisk Inc., Plainsboro, NJ, USA to develop the model and manuscript. Availability of Data and Material: Model input data and source material are reported within the paper and supplemental materials, with the exception of data on file which are not publicly available. Ethical Approval: Not applicable. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Code Availability: Not applicable. Author Contributions: All authors contributed to the study conception and design, data interpretation and analysis, and manuscript revisions. FC was responsible for sourcing the data and model development. All authors read and approved the final manuscript.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief